Beutel Gernot, Ganser Arnold
Department of Hematology, Hemostasis, and Oncology, Hannover Medical School, Hannover, Germany.
Semin Hematol. 2007 Jul;44(3):157-65. doi: 10.1053/j.seminhematol.2007.04.004.
Anemia is frequently diagnosed in patients with cancer and its treatment is an important clinical problem. The deficiency in red blood cells (RBCs) can be a debilitating problem, and anemia correlates with poor performance status, deteriorates quality of life, and may negatively influence the prognosis of cancer patients. The development of recombinant human erythropoietins (rhEPO) provides a therapeutic option in patients with mild to moderate anemia. However, clinical experience demonstrates that more than half of anemic cancer patients are not treated. There is clear evidence that rhEPO reliably increases haemoglobin (Hb) levels in patients suffering from cancer-related or treatment-associated anemia. The dosing and management of these patients should strictly follow evidence-based guidelines of the clinical societies, as well as the manufacturer's recommendations. Furthermore, treatment of patients beyond the correction of anemia must be regarded as potentially harmful and should only be conducted in an experimental clinical setting. In this review, recently published recommendations and standards for the use of rhEPO will be discussed.
贫血在癌症患者中经常被诊断出来，其治疗是一个重要的临床问题。红细胞（RBC）缺乏可能是一个使人衰弱的问题，贫血与身体状况不佳相关，会恶化生活质量，并可能对癌症患者的预后产生负面影响。重组人促红细胞生成素（rhEPO）的研发为轻度至中度贫血患者提供了一种治疗选择。然而，临床经验表明，超过一半的贫血癌症患者未得到治疗。有明确证据表明，rhEPO能可靠地提高患有癌症相关或治疗相关贫血患者的血红蛋白（Hb）水平。这些患者的给药和管理应严格遵循临床学会的循证指南以及制造商的建议。此外，对患者进行超出纠正贫血范围的治疗必须被视为有潜在危害，且仅应在实验性临床环境中进行。在本综述中，将讨论最近发表的关于使用rhEPO的建议和标准。
